Midatech Pharma : Description Report of Foreign Issuer

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF THE

SECURITIES EXCHANGE ACT OF 1934

For the month of, October 2019

Commission File Number 001-37652

Midatech Pharma PLC

(Translation of registrant's name into English)

Oddfellows House,

19 Newport Road,

Cardiff, CF24 0AA, United Kingdom(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-Fx Form 40-F¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

SUBMITTED HEREWITH

Attached to the Registrant's Form 6-K filing for the month of October 2019, and incorporated by reference herein, is:

Exhibit No.

Description

99.1 Press release, dated October 8, 2019 entitled "Commencement of MTD201 Phase 1 Study"

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Midatech Pharma PLC

Date: October 9, 2019

By:

/s/ Stephen Stamp

Stephen Stamp

Chief Financial Officer

Exhibit Index

Exhibit No.

Description

99.1 Press release, dated October 8, 2019 entitled "Commencement of MTD201 Phase 1 Study"

Exhibit 99.1

8 October 2019

Midatech Pharma PLC

("Midatech" or the "Company")

Commencement of MTD201 Phase 1 Study

Midatech (AIM: MTPH.L; NASDAQ: MTP), the R&D biotechnology company focused on delivering innovative oncology and rare disease products to patients, announces that further to the announcement made on 20 September 2019, its MTD201 Phase 1 study ("Study 102") for the treatment of acromegaly and neuroendocrine tumours (NET) has commenced.

The first cohort of healthy volunteers, 14 out of 28 subjects, received one dose of Sandostatin 100 microgram/1 ml solution for injection on 5 October 2019, which was followed yesterday by a 30mg injection of MTD201 via either the subcutaneous or intramuscular route (subjects were randomised between the two groups). The remaining 14 subjects will undergo the same procedures later this week to complete the dosing phase of the study.

Following MTD201 dosing, all subjects enter a 63 day observation and sampling period. This data will then be analysed, with top line results expected by the end of 2019 or early in 2020.

For more information, please contact:

Midatech Pharma PLC

Dr Craig Cook, CEO

Tel: [phone]

www.midatechpharma.com

Panmure Gordon (UK) Limited (Nominated Adviser and Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

James Stearns (Corporate Broking)

Tel: [phone]

IFC Advisory Limited (Financial PR and UK Investor Relations)

Tim Metcalfe / Graham Herring

Tel: [phone]

Email: [e-mail]

Westwicke Partners (US Investor Relations)

Chris Brinzey

Tel: [phone]

Email: [e-mail]

About Midatech Pharma PLC

Midatech Pharma PLC (dual listed on LSE AIM: MTPH; and NASDAQ: MTP) is an R&D company focused on 'Making Medicines Better' by improving delivery of drugs in the body. The Company combines existing medications with its proprietary and innovative drug delivery technologies to provide compelling oncology and rare disease products that have the potential to powerfully impact the lives of patients undergoing treatment for life threatening diseases.